While the historical EPS growth rate for Exelixis is 6.5%, investors should actually focus on the projected growth. The company's EPS is expected to grow 113.1% this year, crushing the industry ...

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Corcept Therapeutics (CORT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Stock Yards Bancorp (SYBT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...